Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

May 2, 2016May 2, 2016

Ontario Labour Federation Calls for Total Ban on Asbestos in Canada

News

Thousands of workers, and their families and friends, gathered across Ontario to mark the National Day of Mourning for Workers Killed or Injured on the Job on April 28. This year, ... Read more

April 15, 2016April 15, 2016

Young Mesothelioma Researcher Among Winners of AXA Achievement Scholarship

News

AXA, a financial services company, recently announced the 52 student winners of the 2016 AXA Achievement Scholarship, one from each of the 50 states in the United States plus Puerto Rico and Washington, ... Read more

April 14, 2016April 14, 2016

U.K. Company Offering Schools Free Training in Asbestos Management Throughout April

News

Each year, the Asbestos Disease Awareness Organisation (ADAO) dedicates April 1-7 to increasing awareness about asbestos and preventing exposure, bringing experts and people with mesothelioma and other asbestos-related diseases together worldwide to ... Read more

April 8, 2016April 8, 2016

COMP Favors Orphan Drug Designation for SELLAS’ WT1 Vaccine to Treat MPM

News

The Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has given a positive opinion in support of orphan drug designation for the WT1 cancer vaccine (galinpepimut-S), which SELLAS Life ... Read more

March 7, 2016March 7, 2016

Mesothelioma Lump-sum Payments Now Open All UK Veterans for Cancer Resulting from Service

News

As a result of a campaign led by The Royal British Legion, all military veterans in the United Kingdom with mesothelioma resulting from their service — regardless of when they were diagnosed ... Read more

March 1, 2016March 1, 2016

Phase 2 Trial of New Mesothelioma Therapy, Using ImmunoGen’s ADC Technology, Getting Underway

News

ImmunoGen, Inc. recently announced it has earned a milestone payment with Bayer’s initiation of a global Phase 2 clinical trial of anetumab ravtansine (BAY 94-9343) as a potential treatment for mesothelioma. ... Read more

February 26, 2016February 26, 2016

EPA Announces Final Cleanup Plan for Asbestos-related Superfund Site in Northwest Montana

News

The U.S. Environmental Protection Agency (EPA) recently announced the final remedial plan for cleaning the Libby and Troy communities affected by the Libby Asbestos Superfund Site in Northwest Montana. The decision ... Read more

February 4, 2016February 4, 2016

In Mesothelioma Patients, Spirulina May Slow Growth of Disease

News

Scientists in China tested the therapeutic potential of polypeptides present in spirulina proteins on different types of cancer, and found significant positive effects on mesothelioma. The study, “Inhibitory effects of small ... Read more

February 1, 2016February 1, 2016

Advanced Mesothelioma Patients Seen to Benefit from Cancer Drug in Clincial Trial

News

A six-year study conducted by French doctors into a new chemotherapy combination for advanced malignant mesothelioma found that bevacizumab added to standard care improved patient survival by inhibiting a vascular endothelial growth factor. The study, “Bevacizumab ... Read more

January 21, 2016January 21, 2016

Mesothelioma Survival Linked to Thoroughness of Tumor Removal

News

Cytoreductive completeness, a measure of how thoroughly a mesothelioma tumor is removed, has far greater impact on peritoneal mesothelioma outcomes than any other factor, according to a recent study in The American Surgeon. ... Read more